Abstract P3-S4.01 Table 1 The laboratory detection of HR-HPV infection in penile (G), urethral (U) and expressed prostate secret (EPS) samples in St. Petersburg (SPb) and Amsterdam (AMS)

Clinics	ClinSPb1		ClinSPb2 LabSPb2	ClinSPb3 LabSPb3	ClinSPb4 LabSPb4	ClinSPb5
	LabAMS1	LabSPb1				
Labs Samples, glans penis	HR-HPV diagnostic test kits					
	LabAMS1	KitRU1	KitRU2			
G1	pos	pos	0	0	0	0
G2	0	0	Pos	0	0	0
G3	pos	pos	0	0	0	0
G4	pos	0	0	0	0	0
G5	pos	0	0	0	0	0
G6	pos	0	0	0	0	0
G7	0	0	0	0	0	0
G8	0	0	0	0	0	0
G9	0	0	0	0	0	0
G10	0	0	0	0	0	0

Anatomical site	HR-HPV positivity	Number of samples tested		HR-HPV concordance, SPb/AMS
		LabSPb3, kitRU2	LabAMS1	
G	(+)Positive	45	15 (33.3%)	3/6 (50.0%)
	(−)Negative		30	27/39 (69.2%)

Anatomical site	HR-HPV positivity	Number of samples tested		HR-HPV concordance, SPb/AMS
		LabSPb1, kitRU1	LabAMS1	
G	(+)Positive	81	29 (35.8%)	18/25 (72.0%)
	(−)Negative		52	45/54 (83.3%)
U	(+)Positive	80	20 (25.0%)	16/23 (69.6%)
	(−)Negative		60	53/57 (92.9%)
EPS	(+)Positive	80	23 (28.8%)	14/17 (83.4%)
	(−)Negative		57	50/55 (90.9%)
All 3 sites	(+)Positive	80	11 (13.8%)	5/9 (55.6%)
	(−)Negative		41	32/40 (80.0%)

programs may be helpful. In Russia reliable figures regarding HR-HPV prevalence remain highly limited. This primarily results from the lack of any internationally valuable screening program on HR-HPV infections among both general population and high-risk groups. This information is important for not only epidemiological purposes and transmission studies but also has a great clinical impact. We investigated the concordance of HR-HPV infection detected in different lab settings across St. Petersburg as compared to the results obtained in Amsterdam to start the first screening program.

Material and Methods In parallel penile (G) and urethral (U) swabs, and expressed prostate secret (EPS) were collected in 134 enrolled in the study on heterosexual men with no STIs tested. The presence of HR-HPV DNA in the penile, urethral swabs and EPS samples was investigated in five commercial clinics/labs in St. Petersburg by two most common in the country diagnostic kits (local manufactures) and in Amsterdam (VU University) by the validated worldwide used GP5+/6+ assay, respectively.

Results The results are presented in the Abstract P3-S4.01 table 1. HPV prevalence in the study group was relatively high: up to 30% (RT-PCR). In house RT-PCR assays used in St. Petersburg five labs showed low similarity and detected less HR-HPV types in urogenital samples as compared to the setting in Amsterdam ($p < 0.0001$).

Discussion Our study showed: (1) HPV prevalence among the Russian population can be high and (2) more anatomical sites in males can be screened: we are the first to report of HPV distribution in three anatomical sites, including EPS. (3) Suboptimal HR-HPV diagnostics observed between techniques used in the study settings St. Petersburg as compared to GP5+GP6+. There is an urgent call

for the internationally valuable HPV screening and detection programs in Russia. At the moment we additionally: (1) extent the study group, (2) include females and (3) investigate the concordance between HPV typing in the labs.

P3-S4.02 HIGH-RISK HUMAN PAPILLOMAVIRUS (HR-HPV) DETECTION IN MEN WITH AND WITHOUT THE HISTORY OF CHLAMYDIA TRACHOMATIS INFECTION

doi:10.1136/sextrans-2011-050108.463

¹V Smelov, ²V Terekhov, ³S Ouburg, ³J Pleijster, ²A Gorelov, ¹A Novikov, ³S Morre. ¹Medical Academy of Postgraduate Studies, St. Petersburg, Russian Federation; ²St. Petersburg State University, St. Petersburg, Russian Federation; ³VU University Medical Center, Amsterdam, Netherlands

Introduction HR-HPV and *C. trachomatis* (CT) are among the most often diagnosed viral and bacterial STIs in the world, respectively. It has been speculated that both of them might be involved in urogenital carcinogenesis and, moreover, potentiate each other's impact and acquisition. The evidence points to a possible association between CT infection history and increased acquisition of HR-HPV infection was investigated among 173 urologist's office male attendees.

Material and Methods Penile and urethral swabs, and expressed prostate secret were collected from 173 heterosexual men visiting an urologist's office to get routinely tested for STDs in the year of 2009 in St.

Petersburg Only heterosexual men with no HIV, gonorrhoea, syphilis and *T vaginalis* were enrolled in the study. CT infection was detected by in-house RT-PCR assay in St. Petersburg and confirmed in Amsterdam by a molecular test (TaqMan). The presence of HR-HPV DNA in the studied samples was investigated in Amsterdam by the validated worldwide used GP5+/6+ assay.

Results The results are presented in the Abstract P3-S4.02 table 1. The overall CT and HPV prevalence in the study group was relatively high: 4.6% and 31.2%, respectively. No significant correlations have been found between HR-HPV findings and CT status ($p=1.0$).

Abstract P3-S4.02 Table 1 Detection of HR-HPV infection in 173 men with/without the history of *C trachomatis* infection

	CT present, detected during the study (prevalence, %)		CT in the past, history of being infected (prevalence, %)	
	CT+	CT–	CT+	CT–
CT infection history	8 (4.6%)	165	45 (35.2%)	128
173 men, in total				
HR-HPV infection, detected in	2 (25%)	53 (32.1%)	14 (31.3%)	40 (31.3%)

Conclusions Our study demonstrated: (1) CT and HPV prevalence among the Russian population can be high, (2) limited co-infection between HPV and CT infections: HR-HPV types were similarly often detected in both CT+ and CT– men, also regardless on their CT acquisition in the past, (3) CT history seems not to increase the HR-HPV acquisition, however, the association between HPV and *C trachomatis* infection still remains to be elucidated and follow-up studies especially among women or homosexuals. 4) All samples found RT-PCR CT+ in Russia were confirmed CT+ using molecular biological techniques in Amsterdam, showing the validity of CT detection in some settings in St. Petersburg. At the moment we additionally: (1) extent the study group, (2) investigate low-risk HPV detection and (3) perform immunogenetic analyses.

P3-S4.03 IMPACT OF COMPREHENSIVE MANAGEMENT INCLUDING COUNSELLING ON HEALTH RELATED QUALITY OF LIFE INDEX IN INDIAN PATIENTS WITH ANOGENITAL WARTS

doi:10.1136/sextrans-2011-050108.464

S Gupta. All India Institute of Medical Sciences, New Delhi, India

Background Health related Quality of life (HRQOL) can be conceptualised as the absence of pain and an ability to function in day-to-day life. Our earlier study has shown that anogenital warts have an adverse effect on HRQOL because of its impact on physical, psychological and sexual health, even though the lesions are often

asymptomatic.¹ To our knowledge, there are no studies available to show the impact of comprehensive management on HRQOL of these patients.

Methods Thirty-five apparently healthy controls (meanage $\pm$ SD 34.8 $\pm$ 11.2) and twenty patients with anogenital warts (mean age $\pm$ SD 32.7 $\pm$ 11.8 years) were included in the study. HRQOL of patients was evaluated using the WHOQOL-BREF instrument at the time of presentation and again after 4 months. During this period, all patients were comprehensively counselled by a trained counsellor and received regular treatment for anogenital warts. The questionnaire was available in local language (Hindi) and was self-administered.

Results All except two patients showed reduction in the size in response to treatment, however complete clearance was seen only in 10 patients (50%). At the baseline, the HRQOL scores of patients were significantly lower than controls in all domains. The HRQOL scores of patients after 16 weeks of comprehensive management were significantly higher than those at the baseline and comparable to those of controls (Abstract P3-S4.03 table 1).

Conclusion Comprehensive management of anogenital warts including counselling has resulted in the significant improvement in HRQOL scores. As anogenital warts are often asymptomatic, the effect on HRQOL appears to be due to its impact on psyche and fear of cancer and interventions including counselling can improve HRQOL more efficiently than in patients with other sexually transmitted diseases.

REFERENCE

1. Rama R, Sreenivas V, Mehta M, *et al*. Health-related quality of life in Indian patients with three viral sexually transmitted infections: herpes simplex virus-2, genital human papilloma virus and HIV. *Sex Transm Infect*. Published Online First: 2 February 2011. doi:10.1136/sti.2010.043356.

P3-S4.04 TOPICAL 80% TRICHLOROACETIC ACID (TCA) SHOWS EFFICACY IN THE TREATMENT OF INTERNAL HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA (HGAIN)

doi:10.1136/sextrans-2011-050108.465

¹K Ho, ¹E Elishaev, ¹D Maciak, ¹J Baker, ²C Parzynski, ²C Zhu, ²R Day, ¹R Cranston. ¹University of Pittsburgh, Pittsburgh, USA; ²University of Pittsburgh Graduate, School of Public Health, Pittsburgh, USA

Background HIV positive men who have sex with men (MSM) are at 60–70 times increased risk of developing anal squamous cell carcinoma than the general population. HGAIN, the putative precursor to cancer, may be ablated by various methods in order to prevent neoplastic progression. While TCA has previously been used clinically to treat keratinised external anal warts, it may also be used to ablate internal HGAIN. Here we report on treatment efficacy and clinical predictors of success.

Abstract P3-S4.03 Table 1 HRQOL Scores in different domains of WHOQOLBREF of patients before and 16 weeks after comprehensive management and those of apparently healthy controls

HRQOL domains	Patients with ano-genital warts			p Value	Healthy controls mean (CI)
	Before comprehensive management mean (CI)	After comprehensive management (at 4 months) Mean (C.I.)			
Physical	40.8 (32.3 to 49.3)	82.1 (77.9 to 86.3)		<0.001	72.0 (63.70 to 80.30)
Psychological	47.55 (37.8 to 57.3)	78 (71.6 to 84.4)		<0.001	68.9 (60.5 to 77.3)
Social	45.05 (35.3 to 54.8)	77.2 (70.8 to 83.6)		<0.001	74.6 (68 to 81.2)
Environmental	51.35 (44.9 to 57.8)	73.55 (16.4 to 130.7)		<0.001	64.7 (58.5 to 71)
Total	184.75 (157.2 to 212.3)	310.85 (294.7 to 327)		<0.001	280.2 (253 to 307.5)
Overall QOL	2.65 (2.2 to 3.1)	4 (3.4 to 4.6)		<0.001	3.5 (3 to 4)
Overall Health	2.7 (2.3 to 3.1)	4.35 (4 to 4.7)		<0.001	3.9 (3.5 to 4.4)
Sexual health	2.95 (2.5 to 3.4)	4.15 (3.9 to 4.4)		<0.001	4.2 (3.8 to 4.5)